
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The company has a strong pipeline of drugs targeting DR3, a novel and difficult-to-target protein involved in inflammatory and immune-mediated diseases. The company's lead asset, SL-325, has the potential to be a first-in-class DR3 antagonist antibody and has shown promising results in preclinical studies. The company also has a second clinical asset, the DR3 x IL-23R bispecific SL-846, which further adds to its pipeline optionality. The company's potential for success is supported by its differentiated approach and its experienced management team. However, as with any biotech company, there are inherent risks such as clinical and regulatory failure, competition from other drugs, and manufacturing challenges that could impact its financial performance. Overall, we believe Shattuck Labs' current market value does not fully reflect the potential value of its platform technology and lead asset, and we see significant upside potential for the stock in the near term.
Bears say
Shattuck Labs is a biotechnology company that focuses on developing treatments for inflammatory and autoimmune diseases. While the company has a promising lead asset, SL-325, clinical trial results for this drug have not met expectations. Additionally, the company's financials show a lack of revenue and a limited cash runway, potentially indicating a lack of resources to support future development.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares